BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

GE Healthcare, Germfree advance manufacturing of novel biotherapeutics

September 13, 2019 | News

The collaboration with Germfree represents a significant contribution to increase capacity and capability in the gene therapy market



GE Healthcare and Germfree are joining expertise to develop a fully integrated, expandable manufacturing solution for emerging biotherapeutics, including gene therapy.

Current market indicators predict a compound annual growth rate of more than 36% in the cell and gene therapy market during 2019-2025. With more than 700 cell and gene therapies currently in clinical trials, demand exceeds supply. The collaboration with Germfree represents a significant contribution to increase capacity and capability in the gene therapy market.

The manufacturing solution will feature a Germfree modular bioprocessing environment based on GE Healthcare's proprietary design and equipped with FlexFactory™, GE Healthcare's integrated single-use biomanufacturing platform. This will be the latest addition to GE Healthcare's KUBio™ prefabricated manufacturing facility offering.